Menopause News and Research

RSS

Menopause is the time in a woman's life when her period stops. It usually occurs naturally, most often after age 45. Menopause happens because the woman's ovary stops producing the hormones estrogen and progesterone.

Women who experience early menopause may have cardiovascular disease later in life: Study

Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

21 Jun 2010

BioSante announces $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

21 Jun 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

Scientists identify symptoms associated with late-onset hypogonadism

Scientists have for the first time identified the symptoms associated with what has been termed late-onset hypogonadism or 'male menopause' caused by a reduction in testosterone production in ageing men.

17 Jun 2010

Study results of genes regulated by ERB published in Journal of Biological Chemistry

Bionovo Inc. today announced the publication of results from a study demonstrating the three distinct classes of genes regulated by estrogen receptor beta. The results are published in the Journal of Biological Chemistry. This is an important discovery for future development of selective drugs regulating this pathway.

11 Jun 2010

2010 GAPS sheds light on the painful reality of what life is like for gout patients

The 2010 Gout Attitudes Patient Survey, a new study of Americans with gout, released by Men's Health Network, sheds light on the painful reality of what life is like for the approximately five million Americans who live with this condition. Of those surveyed, 69 percent described the pain of a gout attack as "miserable," yet a quarter of gout patients feel that those without gout perceive them as overreacting to attacks, and 67 percent feel as though others do not take the condition seriously.

11 Jun 2010

Therapies for female sexual dysfunction

Many women experience problems in the bedroom at one time or another. Female sexual dysfunction is not uncommon and although some women and healthcare providers have difficulty discussing it, it has been recognized by the medical community for decades. In fact, for the last twenty years, it has been listed in the Diagnostic and Statistical Manual of Mental Disorders, a manual published by the American Psychiatric Association, used to classify and diagnose psychological disorders.

10 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

HRT patches containing low doses of oestrogen carry less risk of stroke than oral therapy: Study

Hormone replacement therapy skin patches containing low doses of oestrogen carry less risk of stroke than oral therapy and may represent a safer alternative to tablets, suggests a study published on bmj.com today.

4 Jun 2010

Researchers identify new therapeutic target for cognitive decline

Researchers at Mount Sinai School of Medicine have found that certain types of specializations on nerve cells called "spines" are depleted as a person ages, causing cognitive decline in the part of the brain that mediates the highest levels of learning.

3 Jun 2010

Discovery provides new therapeutic target to prevent brain function loss

3 Jun 2010

Egg donation is not a simple process

Jennifer was a junior in college when she decided to donate her eggs to a couple undergoing fertility treatments. Like most donors, she was primarily motivated by altruism. But she admits that the compensation -- $7,000 – didn't hurt.

3 Jun 2010

European Society of Human Reproduction and Embryology 2010 meeting set for June 27-30 in Rome, Italy

New research findings from fertility experts from Europe, the Americas, Asia & Australasia

31 May 2010

Advances in women's health, practice of obstetrics and gynaecology to be discussed at SOGC

The 66th Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada. Leading international and Canadian experts will meet to discuss the latest knowledge and advances in women's health and in the practice of obstetrics and gynaecology.

29 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

Study demonstrates need for understanding societal, economic impact of growing medicalization

Menopause. Normal pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several decades, these conditions have come to be defined and treated as medical problems. They've been "medicalized." In the first study of its kind in the current issue of Social Science and Medicine, Brandeis researchers used national data to estimate the costs of these and a handful of other common conditions on escalating U.S. healthcare spending.

19 May 2010

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

Female sex hormones may work with estrogen in reducing airway constriction: Research

Female sex hormones may work with beta-agonists in reducing airway constriction, according to new bench research from the Mayo Clinic.

17 May 2010

Fat tissue different in men and women

The age-old question of why men store fat in their bellies and women store it in their hips may have finally been answered: Genetically speaking, the fat tissue is almost completely different.

15 May 2010

Menopause News and Research

Further Reading

Women who experience early menopause may have cardiovascular disease later in life: Study

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante announces $15 million registered direct offering

BioSante announces presentation of LibiGel safety update at ENDO 2010

Scientists identify symptoms associated with late-onset hypogonadism

Study results of genes regulated by ERB published in Journal of Biological Chemistry

2010 GAPS sheds light on the painful reality of what life is like for gout patients

Therapies for female sexual dysfunction

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

HRT patches containing low doses of oestrogen carry less risk of stroke than oral therapy: Study

Researchers identify new therapeutic target for cognitive decline

Discovery provides new therapeutic target to prevent brain function loss

Egg donation is not a simple process

European Society of Human Reproduction and Embryology 2010 meeting set for June 27-30 in Rome, Italy

Advances in women's health, practice of obstetrics and gynaecology to be discussed at SOGC

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

Study demonstrates need for understanding societal, economic impact of growing medicalization

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Female sex hormones may work with estrogen in reducing airway constriction: Research

Fat tissue different in men and women

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News